filmov
tv
New antiviral drug in trials
Показать описание
Novel oral antiviral for SARS-CoV-2 progresses in Phase I trial, Protease inhibitor
Background science
Viral proteases are enzymes, endopeptidases
Encoded by the genetic material (DNA or RNA) of viral pathogens
Catalyze cleavage of specific peptide bonds in viral precursors
These proteolytic events are essential for the completion of the viral infectious cycle
Protease inhibitors, bind to a viral enzyme, called a protease
Prevent the virus from replicating
Protease inhibitors, used to treat HIV and hepatitis C
Assess tolerability and safety of multiple ascending doses of PF-07321332
Phase I study, healthy adults
Randomised, double-blind, sponsor-open, placebo-controlled, single- and multiple-dose escalation study in healthy adults evaluating the safety, tolerability and pharmacokinetics of PF-07321332.
Protease inhibitor, demonstrated potent in vitro antiviral activity against SARS-CoV-2 and other coronaviruses.
Could be prescribed orally at the first sign of infection
Pfizer also investigating an intravenously administered protease inhibitor, PF-07304814, in hospitalised patients with COVID-19.
November??
Background science
Viral proteases are enzymes, endopeptidases
Encoded by the genetic material (DNA or RNA) of viral pathogens
Catalyze cleavage of specific peptide bonds in viral precursors
These proteolytic events are essential for the completion of the viral infectious cycle
Protease inhibitors, bind to a viral enzyme, called a protease
Prevent the virus from replicating
Protease inhibitors, used to treat HIV and hepatitis C
Assess tolerability and safety of multiple ascending doses of PF-07321332
Phase I study, healthy adults
Randomised, double-blind, sponsor-open, placebo-controlled, single- and multiple-dose escalation study in healthy adults evaluating the safety, tolerability and pharmacokinetics of PF-07321332.
Protease inhibitor, demonstrated potent in vitro antiviral activity against SARS-CoV-2 and other coronaviruses.
Could be prescribed orally at the first sign of infection
Pfizer also investigating an intravenously administered protease inhibitor, PF-07304814, in hospitalised patients with COVID-19.
November??
Комментарии